Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

← catalyst calendar

NCT07108894 · readout ≤ 254 d

Sponsored by AbCellera Biologics Inc. (industry) · ABCL — their whole pipeline →.

Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
40estimated
Sites
1
Country
Canada

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2025-07-25actualWhen the study began enrolling
Primary completionApr 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionApr 2027estimatedThe whole study's end, after follow-up
First posted2025-08-07actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-16actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Healthy Volunteers

Interventions

  • Biological: ABCL575
  • Biological: Placebo (Normal Saline 0.9%)

Primary outcomes

what the primary-completion date above is the date OF
Incidence, frequency, and severity of adverse events (AEs)
measured Day 0 to day 337
Changes from baseline in laboratory parameters including general biochemistry, lipid profile, coagulation, hematology, and urinalysis
measured Day 0 to day 337
Changes from baseline in physical examination
measured Day 0 to day 337
Changes from baseline in vital signs
measured Day 0 to day 337
Changes from baseline in 12-lead safety ECGs
measured Day 0 to day 337
Incidence and severity of injection site reactions
measured Day 0 to day 337

Permalink · ABCL's whole pipeline · Catalyst calendar · Every registered study · What changed